Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes BIGboy7 and Anthazar and Obiwan!! WOOHOO PRED $4 billion dollar company in 2 more months!
Yeah it always falls before it rises. That's why were at $20 in 2020.
.18 cents to $18 on 100/1 RS.
Thanks nice job.
wow woo wee whats your avg? Below .10?
How do you arrive at the number? Metrics? income? WAG?
I guess that's how all the management is at PRED. NO INTEGRITY just ask all the companies they've stiffed.
After the reverse split it will fall right back to .20 cents great time to short it at $20
No real value created..... all smoke and mirrors thanks for admitting your predictions are pure BS.
Just wait for .02 that's the most likely scenario. Expect the expected.
This dog can't hunt.
Did you hear the new merger with pred and mmmm, bnfh, kpay & ewll? The new symbol is going to be OCRAP!
Won't be long now for this to get to the BIG MAN's prediction of .02 in 2020.
HILARIOUS! LMFAO yeah not .20 cents .02 cents is more like it.
PRED some big boy buyers came in and bought 15 shares. WOO WEE massive volume. Where are all the form 4's?
Unfortunately for US we will never forget this nightmare.
This stock is one DEAD POS> In a year when someone mentions PRED the question will be what's PRED?
We were told RIGHT HERE by the BIG MAN $35 in 2020. Just think if it got to .35 cents it would be a miracle.
I was hoping we'd get at least a penny/share dividend paid monthly. (.12 a year.) LMFAO At least while we wait for the stock to return to $5+ so we can recoup our losses.
PRED the nightmare of my life! $6.91 to .0126 and no one wants it as per the volume so low they can't give it away. Oh wait they just gave Brad another 2+ million shares.
No doubt this was the best short from the high 2's. One over valued oink oink.
Yes one over valued stonk of my life.
Yeah YUGE demand for this ticker 100 shares traded. I love how they said Nasdaq listing coming. Then the 10K says there won't be any Nasdaq coming if ever. And they'll be lucky to get back on the pink sheets, and that won't be anytime soon. Just like the millions of covid tests would be sold. I said they aren't selling any. BOOM right there in black and white.
We have not sold any ASSurance AB tests.
As mazz pointed out those are not even needed at this time. OOPS
The only monster getting released is an increase in the bloated float!
Low .06's high 5's for everyone! PUN intended.
What's so interesting is that I was right all along there were no ASSurance AB tests selling!!!!!!!
Hey how many ASSurance AB kits did they sell? YEAH NONE! LOL
Didn't you say they would be selling millions of them? LOL
Just think what they could of done with H&R block for half the cost!
The only brochure that should be in the waiting room is from the SEC to avoid penny stock scams.
Brad's bloated shares goes higher from 42 million to 44,492,482.
I guess he desrve those along with over paid salary of 300k.
Our common stock is not listed on a major exchange and there is no assurance that we will be able to obtain such a listing.
Our common stock currently trades on the Over-The-Counter markets under the symbol PRED. As a result of the suspension of trading in our stock by the SEC in April 2020, trading in our stock was moved from the PTC Pink Sheets to the OTC Gray Sheets. The Over-The-Counter market in general and the Gray sheets in particular are considered to be a less efficient system than listing on markets such as NASDAQ or other national exchanges because of lower trading volumes, transaction delays and reduced security analyst and news media coverage. These factors could contribute to lower prices and larger spreads in the bid and ask prices for our common stock. Additionally, trading of our common stock on the Over-The-Counter markets may make us less desirable to institutional investors and may, therefore, limit our future equity funding options and could negatively affect the liquidity of our stock.
We are seeking to resume trading on the OTC Pink Sheets and simultaneously seeking a listing on NASDAQ. There can be no assurance that our common stock will qualify to resume trading on the OTC Pink Sheets. We currently do not qualify for a listing on NASDAQ and there can be no assurance that we will qualify for a NASDAQ listing in the future. In addition, if a NASDAQ listing is obtained then we will be subject to continued listing requirements to maintain the listing and to avoid delisting. Our results of operations and our current and fluctuating stock price directly impact our ability to satisfy these listing standards.
More good news!
There can be no assurance of market acceptance for our Assurance VRâ„¢ COVID-19 RT-PCR viral test.
In July 2020, the Company validated a saliva-based RT-PCR viral test for COVID-19 that is being marketed as Assurance VRâ„¢. The test has been granted Emergency Use Authorization by the FDA. The commercial success of our Assurance VRâ„¢ COVID-19 test will depend upon its acceptance as medically useful and cost-effective by physicians and other members of the medical community, patients, and third-party payers. Broad market acceptance can be achieved only with substantial education about the benefits and limitations of such tests, as well as resolution of concerns about their appropriate use. We or our potential distributor, if any, may be required to expend substantial financial resources to responsibly promote the benefits of our Assurance VRâ„¢ COVID-19 test. There can be no assurance our Assurance VRâ„¢ COVID-19 antibody test will gain market acceptance on a timely basis, if at all. Failure to achieve market acceptance will have a material adverse effect on our business, financial condition, and results of operations.
Risks Related to FDA Approval
As noted, our initial commercial genetics product will be an LDT, conducted in a CLIA-certified laboratory, for indications of endometriosis, which will be marketed to Assisted Reproductive Therapy centers and subsequently to the broader OB/GYN physician marketplace. We believe that this product does not require FDA approval. We currently contemplate the eventual launch of a test "kit", to be marketed as a companion diagnostic for on-label therapeutic indication. We believe that such a kit would be subject to the FDA approval process, including clinical trials. The FDA Approval process can be an extended, complex, and expensive process. No assurances can be given that, in the event we do elect to pursue a kit, FDA approval will be granted
There can be no assurance of regulatory or market acceptance for our Assurance ABâ„¢ COVID-19 antibody test.
The commercial success of our Assurance ABâ„¢ COVID-19 antibody test will depend upon its acceptance as medically useful and cost-effective by physicians and other members of the medical community, patients, and third-party payers. Broad market acceptance can be achieved only with substantial education about the benefits and limitations of such tests, as well as resolution of concerns about their appropriate use. We or our distributor, if any, may be required to expend substantial financial resources to responsibly promote the benefits of our Assurance ABâ„¢ COVID-19 antibody test. Demand for the Assurance ABâ„¢ test may be significantly limited or eliminated if the FDA does not grant an Emergency Use Authorization (EUA) for the test. The test is currently under review by the FDA and an EUA may not be granted timely or at all. There can be no assurance our Assurance ABâ„¢ COVID-19 antibody test will gain market acceptance on a timely basis, if at all. Failure to achieve regulatory or market acceptance will have a material adverse effect on our business, financial condition, and results of operations.
There can be no assurance that we will be able to maintain or develop appropriate distribution arrangements that will be necessary for us to develop and commercialize our Assurance ABâ„¢ COVID-19 antibody test.
In April 2020, we signed an exclusive distribution agreement for the Assurance ABâ„¢ test with Wellgistics, LLC. Wellgistics failed to pay the entire deposit amount stipulated in the agreement, and no product has been delivered to them. As a result of the failure to make payment, Wellgistics is no longer the exclusive distributor of Assurance ABâ„¢. There can be no assurance that Wellgistics, LLC will meet its contractual commitments or be able to successfully market and distribute our Assurance ABâ„¢ COVID-19 antibody test. In addition, there can be no assurance that Wellgistics, LLC or any other future collaborative partner will not pursue alternative technologies or develop alternative products either on their own or in collaboration with others, including with our competitors, as a means of developing competitive tests. There is no assurance that we can successfully replace Wellgistics, LLC with one or more future distributors. Failure of any distribution arrangement could have a material adverse effect on our business, financial condition, or results of operations. A dispute with our current or any future distributor could lead to delays in test sales, or could result in litigation or arbitration, any of which could have a material adverse effect on our business, financial condition or results of operations.
We may not be successful in developing diagnostic tests or in correctly interpreting the results of our diagnostic tests.
No kidding does seem they can't sell much of those yet.
Whether we will be successful in offering diagnostic testing depends in large part upon our ability to develop genetic tests for genes we have discovered. We are seeking to develop genetic tests that can identify the existence of a particular gene mutations that predispose a person to a particular disease. These gene mutations cannot be discovered until the relevant genes have been discovered and fully sequenced. Genes can be complex and may have numerous mutations. Moreover, a defective gene may malfunction in many different ways, and the many mutated versions of the gene may make a genetic test difficult to perform and interpret. Until a mutation has been characterized, researchers cannot say for sure what risk it poses for an individual. Further, even when a genetic test identifies the existence of a mutation in a particular individual, the interpretation of the genetic test results is limited to the identification of a statistical probability that the tested individual will develop the disease for which the test has been completed. There can be no assurance that we will be successful in developing genetic tests based on our gene discoveries or other such tests will be able to be marketed at acceptable prices or will receive commercial acceptance in the market.
We may not be successful in obtaining adequate reimbursement for our services and products.
Our ability to successfully commercialize any genetic test or treatments we develop, and the ability of any future collaborative partners, if any, to successfully commercialize such products, depends in part on obtaining adequate reimbursement for such services and products and related treatments from government and private health care insurers (including health maintenance organizations) and other third-party payers. Physicians' decisions to recommend genetic tests and treatments, as well as patients' elections to pursue testing and treatments, are likely to be heavily influenced by the scope and extent of coverage for such tests by third-party payers. Government and private third-party payers are increasingly attempting to contain health care costs by limiting both the extent of coverage and the reimbursement rate for new diagnostic and therapeutic products and services. In particular, services which are determined to be investigational in nature or which are not considered "reasonable and necessary" for diagnosis or treatment may be denied reimbursement coverage. If adequate reimbursement coverage is not available from third-party payers, there can be no assurance that individuals will elect to pay directly for the genetic testing and treatments and market acceptance of the genetic testing and treatments will likely be adversely impacted, which would have a material adverse effect on our business, financial condition and results of operations.
Our existing capital resources will not meet our current needs and we must raise additional funding in the immediate future to execute our business plan.
Available funding may not be sufficient to execute our business plan over the next twelve months and thereafter. There can be no assurance that the necessary funds will be timely available if needed or that continuing operations will provide the needed cash flows.
Our financial resources are insufficient to repay amounts owed on outstanding liabilities.
Our cash reserves are not sufficient to pay current liabilities. We will be looking to pay these obligations through debt or equity financings and/or revenues from operations. We do not have any financial commitments with respect to future financings, we have found it difficult to raise funding in recent periods, and we have had negative cash flow from operating activities during most periods of our operating history. As a result, there can be no assurance that we will have the means to repay our obligations in full or at all.
-20-
We rely on a single laboratory facility to process our molecular diagnostic tests and a second single laboratory facility to produce our regenerative medicine products and HCT/Ps.
We rely on a single CLIA-certified, CAP accredited laboratory facility in Salt Lake City, Utah that we lease and operate to process our molecular diagnostic tests. We rely on a second laboratory facility in Salt Lake City, Utah that we lease and operate to process our regenerative medicine products and HCT/Ps. These facilities and certain pieces of laboratory equipment would be difficult to replace and may require significant replacement lead-time. These facilities could be affected by natural disasters such as earthquakes, floods, and fires. In the event either of these facilities or the equipment located in the facilities are affected by man-made or natural disasters, we would be unable to continue our genetic and/or molecular diagnostic business and meet customer demands for a significant period of time. Any interruption in our molecular diagnostic and/or regenerative medicine business would result in a loss of goodwill, including damage to its reputation. If our regenerative medicine and/or planned molecular diagnostic business were interrupted, it would seriously harm our business.
Looks like the naysayers were right NO Assurance AB test sold! At least not yet, but there is hope right? Maybe before the vaccines come out?
June 2020, the Company separately imported 200,000 Assurance ABâ„¢ units under a consignment agreement. The Company is not obligated to pay for units until they are sold, and the Company may return the units after six months. No units have been sold to date as the Company is awaiting a decision on its application for an Emergency Use Authorization from the FDA.
Have they sold any of these?
ASSurance VRâ„¢
The Company introduced the Assurance VR COVID-19 RT-PCR test in July 2020. The Assurance VR COVID-19 viral test is intended for the qualitative detection of SARS-CoV-2 coronavirus during the acute phase of COVID-19 infection. Assurance VR is intended for individuals suspected of COVID-19 infection by a healthcare provider. Assurance VR uses a saliva sample to detect the presence of the SARS-CoV-2 coronavirus genetic material (RNA) using a process called RT-PCR. The sample is processed and results delivered by Predictive Laboratories, a high-complexity CLIA laboratory. Assurance VR uses the EUA approved Thermo Fisher TaqPath COVID-19 Combo Kit for the detection of the SARS-CoV-2 virus. Assurance VR samples are collected using an EUA approved at-home saliva sample collection kit produced by Spectrum Solutions, LLC. This collection device is easier, less intrusive and safer for health care workers than nasopharyngeal or oropharyngeal swabs.
Very smart run from this theiveing ceo.
Sorry I wouldn't own this smoking hot turd!
RL is right today's cheapies will be next months expensive shares.
From .35 to .06 in 8 years! I wouldn't touch this bloated POS with 1000' pole.
What makes you think this will rise with a bloated float heading to 1.5 BILLION?
They'll be plenty of opportunities to get cheap shares and cheaper and cheaper.